Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim CoeditorIndividualAuthor
In Reply: Drs Klovning and Norheim correctly
point out that results from subgroups should be regarded cautiously, especially
if the results come from indiscriminate analyses of subgroups that are planned
after the main results are known. This is not the case in our study. As we
noted in the article, "Before unblinding, we planned to analyze the effects
of alendronate on the risk of clinical fractures, vertebral fractures, and
bone densities in subgroups stratified by tertile of baseline . . . femoral
neck BMD." We did not plan to, and therefore we will not, analyze the data
by quintiles or quartiles.
Cummings SR. Alendronate and Fracture Prevention—Reply. JAMA. 1999;282(3):231. doi:10-1001/pubs.JAMA-ISSN-0098-7484-282-3-jac90006
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: